Arthriten Inflammatory Pain Formula 250 mg/1
acetaminophen, aspirin, caffeine · TABLET, FILM COATED · Kobayashi Healthcare International, Inc
Arthriten Inflammatory Pain Formula is a tablet, film coated containing acetaminophen, aspirin, caffeine at 250 mg/1, taken oral. Manufactured by Kobayashi Healthcare International, Inc.
Key Facts
- Brand Name
- Arthriten Inflammatory Pain Formula
- Generic Name
- acetaminophen, aspirin, caffeine
- NDC Code (Product)
52389-237- Manufacturer
- Kobayashi Healthcare International, Inc
- Strength
- 250 mg/1
- Dosage Form
- TABLET, FILM COATED
- Route
- ORAL
- Marketing Status
- Application #
- M013
- Drug Class
- Nonsteroidal Anti-inflammatory Drug [EPC]; Platelet Aggregation Inhibitor [EPC]
- Marketing Start
- 07/23/2012
Recall History
No Recall HistorySide Effects Reported to FDA
FDA FAERS database · These are reported events, not confirmed side effects
Full Prescribing Information
Indications & Usage
Uses For the temporary relief of minor aches and pains including the minor pain of arthritis.
Dosage & Administration
Directions Read all package directions and warnings before use and use only as directed. Adults: Two (2) caplets every 6 hours while symptoms persist, not to exceed 4 doses (8 caplets) in 24 hours, or as directed by a doctor. Drink a full glass of water with each dose Intended for use by normally healthy adults only Persons under 18 years of age should use only as directed by a doctor.
Warnings
Warnings Reye's Syndrome: Children and teenagers who have or are recovering from chicken pox or flu-like symptoms should not use this product. When using this product, if changes in behavior with nausea and vomiting occur, consult a doctor because these symptoms could be an early sign of Reye's Syndrome, a rare but serious illness. Allergy alert: Aspirin may cause a severe allergic reaction which may include: hives facial swelling asthma (wheezing) shock Acetaminophen may cause severe skin reactions. Symptoms may include: skin reddening blisters rash If skin reaction occurs, stop use and seek medical help right away. Liver warning: This product contains acetaminophen. Severe liver damage may occur if you take more than 8 caplets in 24 hours, which is the maximum daily amount for this product. with other products containing acetaminophen 3 or more alcoholic drinks every day while using this product. Stomach bleeding warning: This product contains a non-steroidal anti-inflammatory drug (NSAID), which may cause severe stomach bleeding. The chance is higher if you are age 60 or older have had stomach ulcers or bleeding problems take a blood thinning (anti-coagulant) or steroid drug tak…
Frequently Asked Questions
What is Arthriten Inflammatory Pain Formula used for?
Arthriten Inflammatory Pain Formula contains acetaminophen, aspirin, caffeine. It is a tablet, film coated taken oral. Consult your doctor for specific uses.
Is Arthriten Inflammatory Pain Formula a controlled substance?
Arthriten Inflammatory Pain Formula is not classified as a controlled substance by the DEA.
What is the generic name for Arthriten Inflammatory Pain Formula?
The generic name for Arthriten Inflammatory Pain Formula is acetaminophen, aspirin, caffeine. There are 11 other brand versions of acetaminophen, aspirin, caffeine.
What is the NDC code for Arthriten Inflammatory Pain Formula 250 mg/1?
The NDC (National Drug Code) for Arthriten Inflammatory Pain Formula 250 mg/1 is 52389-237, listed by Kobayashi Healthcare International, Inc.
Other Acetaminophen, Brands
See all →- basic care migraine relief250 mg/172288-374
- MIGRAINE FORMULA250 mg/179481-0211
- good sense migraine formula250 mg/182804-002
- Headache Relief250 mg/183324-063
- Headache Relief250 mg/183324-331
- EXTRA STRENGTH PAIN RELIEF250 mg/121130-037
- Headache Relief Extra Strength250 mg/121130-586
- topcare migraine relief250 mg/136800-934
- Excedrin Extra Strength Headache250 mg/150269-158
- dg health headache relief250 mg/155910-639
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)